China's National Medical Products Administration accepted the marketing application of Humanwell Healthcare's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, for landiolol hydrochloride for injection, according to a Shanghai bourse filing on Thursday.
The drug is used for the treatment of tachyarrhythmias in patients with heart failure or during surgery.
The pharmaceutical company invested 9.5 million yuan into the research and development of the drug.